Approval · Notice of Compliance 10163 · 2009
ARIMIDEX: Notice of Compliance 10163
Issued April 20, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10163
- Date
- April 20, 2009
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the following sections in the Product Monograph: Warnings and Precautions, Clinical Trial Adverse Drug Reactions, and Clinical Trials
- Therapeutic class
- Non-steroidal aromatase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ARIMIDEX | Not yet assigned | — |
Medicinal ingredients
- ANASTROZOLE 1 MG per TAB